Fierce Pharma published this morning that at least 3 generic manufacturers may be interested in buying Pfizer's "value products business", off patent and soon to be off paent drugs. The companies named as possible suitors include: Valeant, Mylan and Actavis. Pfizer remained coy when asked for any comment.
Valeant is an experienced acquirer but just pulled off an $8.7 B acquisition of Bausch & Lomb and the price to acquire a Pfizer company that had $7 B in sales in its last 3 quarters may just be too much to bear. Mylan and Actavis are considered contenders as they both race to gain number one share in the generics market. Actavis stands at about $11 B in sales now. Mylan is significantly smaller with about $6.7 B in current sales. For now this is all conjecture, but it is fun to speculate no?
Posted by Bruce Lehr Jan 17th 2014.